These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 6220307)
21. Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapy. Alexanian R; Migliore PJ J Lab Clin Med; 1970 Feb; 75(2):225-33. PubMed ID: 5414404 [No Abstract] [Full Text] [Related]
22. Carcinoma of the breast. Occurence after treatment with melphalan for multiple myeloma. Bell R; Sullivan JR; Fone DJ; Hurley TH JAMA; 1976 Oct; 236(14):1609-10. PubMed ID: 183029 [No Abstract] [Full Text] [Related]
23. [Treatment of multiple myeloma with melphalan: 35 personal cases]. Dryll A; Ryckewaert A; Kahn MF; Hayat M; de Seze S Sem Hop; 1970 Jan; 46(5):289-98. PubMed ID: 4327260 [No Abstract] [Full Text] [Related]
24. Multiple myeloma terminating in acute leukemia: report of two cases and review of the literature. Martínez-Poventud G; Fernández AC; Vélez-García E Bol Asoc Med P R; 1985 Oct; 77(10):419-21. PubMed ID: 3865657 [No Abstract] [Full Text] [Related]
26. [Refractory anemia with partial myeloblastosis in multiple myeloma treated with melphalan]. Morlock G; Bataille R; Sany J; Serre H Sem Hop; 1977 Apr 9-16; 53(14-15):853-6. PubMed ID: 194338 [No Abstract] [Full Text] [Related]
27. Breast cancer and acute leukemia in a patient with multiple myeloma treated with melphalan. Meytes D; Katz DR Isr J Med Sci; 1973 Aug; 9(8):1044-7. PubMed ID: 4753846 [No Abstract] [Full Text] [Related]
28. [Dysmyelopoietic syndrome 7 years after melphalan treatment of multiple myeloma. Clinical case]. Scolozzi R; Boccafogli A Minerva Med; 1983 Jul; 74(28-29):1783-5. PubMed ID: 6866310 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Borad MJ; Swift R; Berenson JR Leukemia; 2005 Jan; 19(1):154-6. PubMed ID: 15496977 [No Abstract] [Full Text] [Related]
30. Cyclophosphamide vs melphalan in treatment of plasma cell myeloma. Rivers SL; Patno ME JAMA; 1969 Feb; 207(7):1328-34. PubMed ID: 4179565 [No Abstract] [Full Text] [Related]
31. [Acute myeloproliferative syndrome after alkylating agent treatment in a case of multiple myeloma]. Gardella S; Cervantes F; Bladé J; Brugués R; Rozman C Med Clin (Barc); 1982 Sep 1-15; 79(4):185-8. PubMed ID: 7144293 [No Abstract] [Full Text] [Related]
32. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. Offidani M; Marconi M; Corvatta L; Olivieri A; Catarini M; Leoni P Haematologica; 2003 Dec; 88(12):1432-3. PubMed ID: 14688003 [No Abstract] [Full Text] [Related]
33. Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. Roy V; Stewart AK; Bergsagel PL; Dispenzieri A; Laumann K; Allred J; Lacy MQ; Fonseca R; Reeder CB; Kumar S; Rivera CE; Gertz MA; Buadi FK; Hayman SR; Rajkumar SV Blood Cancer J; 2015 Mar; 5(3):e294. PubMed ID: 25794130 [No Abstract] [Full Text] [Related]